Dina Chaya

Partner, Neomed Management

BD

Bernard Davitian

Partner

Michelle Doig

Partner Head of Corporate Development

Francesco Draetta

Principal

KK

Katie Kerfoot

VP

Annie Mitsak

Principal

Vincent Ossipow

Partner, Neomed Management

Anne-Mari Paster

MD

MR

Mark Russell

Chief Compliance Officer, VP, Finance

Otello Stampacchia

MD

120 past transactions

Acrux

Venture Round in 2004
Acrux is a specialty pharmaceutical company, developing and commercialising a range of patented, patient-preferred healthcare products for global markets, using its innovative technology to administer drugs through the skin. Acrux's product pipeline includes treatments of hormonal deficiencies, pain, central nervous system disorders and a contraceptive. 20 human clinical trials have been completed with 8 different drugs and the lead product, Evamist(TM), is nearing the end of a phase 3 trial in the USA.

OnPath Technologies

Venture Round in 2011
ONPATH Technologies provides scalable connectivity and monitoring solutions for high-performance networks. The company is a spin-out of Brocade Communications’ physical layer switch business. ONPATH’s Universal Connectivity System and HorizON Software platform automates data center and test infrastructure as an alternative to manual patching or mesh switching architectures. The platform is scalable from 8 to 4,096 non-meshed ports, independent of speed or protocol requirements. The company serves Cloud Networking, Test Automation, Network Monitoring, and Cyber Security application areas. It is based in Marlton, New Jersey.

Aquarius Technologies

Venture Round in 2010
Aquarius Technologies is an Israeli cleantech company that develops wastewater treatment solutions. Aquarius Technologies has over a decade of industry experience with over a million diffused aeration products in service and biological solutions installed throughout the world. Aquarius Technologies is committed to establishing lifetime customer relationships. Its aeration and biological systems provide customers with a solution representing the lowest cost of ownership. The company was established in 2006 and is based in Saukville, Wisconsin.

Morphic Holding, Inc.

Series A in 2016
Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Drawing on discoveries made in the lab of Scientific Founder Tim Springer, Morphic was created in 2015 with co-founders Polaris Partners, T.A. Springer and Schrödinger, Inc., along with ShangPharma Investment Group.

Synthekine Inc.

Series B in 2021
Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.

Enanta Pharmaceuticals

Venture Round in 2001
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

LEXEO Therapeutics

Series B in 2021
LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (single genemutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline.

Thankful, Inc.

Series A in 2021
Thankful, Inc. develops an artificial intelligence platform known as Thankful which deflects queries. The platform allows modifying scripts, managing the team, and monitoring thankful's accuracy and impact over time. Its features include questions and answers auto replies, information gathering, ticket routing, e commerce actions, advanced scripts, and team management. Thankful, Inc. is headquartered in Los Angeles, California.

Develogen AG

Venture Round in 2004
Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States.

Achaogen

Venture Round in 2007
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.

amunix

Series A in 2020
Amunix Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops protein and peptide therapeutics products for cancer. It focuses on XTEN, a half-life extension platform; XPAT (XTENylated Protease-Activated T Cell Engager) platform using its XTEN technology to analyze protease activity in the tumor microenvironment; and Protease Triggered Immune Activator (ProTIA), an immuno-oncology therapeutic. The company caters to the academic, biotechnology, and pharmaceutical sectors. It has strategic partnerships with Janssen, Biogen-Idec, Noxxon, Baxalta, Ambrx, Seattle Genetics, and Versartis. The company was formerly known as Amunix, Inc. Amunix Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Mountain View, California.

Exenta, Inc.

Venture Round in 2011
Your business is growing quickly, but things on the manufacturing side are disconnected and unknown. Exenta, Inc. Shopfloor 3PMTM brings real-time visibility and control to the forefront. Timing : Mon - Fri 09:00 AM to 06:00 PM, Sat - Sun - Closed Address : 8 W 38th St, New York, NY 10018

CymaBay Therapeutics, Inc.

Venture Round in 2004
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.

HydroCision, Inc.

Venture Round in 2010
HydroCision develops, manufactures, and markets fluidjet based surgical tools for minimally invasive spine surgery requirements. Its products include SpineJet HydroSurgery System that is used to ablate, cut, and remove targeted tissue for spinal procedures, Spinejet, water-based technology solutions for minimally invasive spine surgery requirements, SpineJet HydroDiscectomy Systems, which are used to remove tissue without the risk of thermal energy for minimally invasive discectomy procedures, and AlloJet, systems to prepare bone allografts. The company also provides customer care services. HydroCision, Inc. was formerly known as Surgijet Corporation and changed its name to HydroCision, Inc. in November 1996. The company was founded in 1994 and is headquartered in North Billerica, Massachusetts.

Evotec AG

Venture Round in 2004
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates, and consulting arrangements. The company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes, and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, and fibrosis. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased, and comprehensive infrastructure. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB, and others. In addition, the company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Sanofi in the field of diabetes and cancer immunotherapy, with Pfizer in the field of tissue fibrosis, with Bayer in the field of kidney diseases, and with Celgene in the field of neurodegenerative diseases.

Endeavor BioMedicines

Series B in 2022
Endeavor BioMedicines is developing new treatments targeting the underlying causes of pulmonary fibrosis.

Ardana Bioscience

Venture Round in 2004
Ardana Bioscience was created in July 2000 to commercialise research by the Medical Research Council (MRC )'s Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland which has been at the forefront of this area of research for the last 28 years. The MRC employs nearly 100 staff at the Unit which currently receives total annual funding of £3.8 million.

CropDesign

Venture Round in 2004
CropDesign is a biotechnology company delivering traits for the global seed market and for plant-based products. CropDesign uses its proprietary TraitMillTM platform to discover genetic traits for the improvement of corn, rice and other plants. Founded in 1998, CropDesign employs more than 70 people at its research facilities in Gent, Belgium and has an extensive network of research and commercial partners.

Epigenomics AG

Venture Round in 2002
Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, Asia, and internationally. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer using its proprietary DNA methylation biomarker, Septin9. The company also offers Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its development pipeline also contains products for screening, early detection, and diagnosis of cancers. In addition, the company engages in the identification of biomarker opportunities for various cancers, such as bladder cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

Visterra

Series A in 2012
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

NeuroVision Imaging LLC

Venture Round in 2014
NeuroVision is an integrated neuroscience company focused on delivering scientifically validated, diagnostic tests & biomarkers for early detection and monitoring of amyloid pathology related to Alzheimer’s Disease. The company has developed a novel retinal imaging technology, which is currently being utilized in a number of clinical trials globally.With access to unique datasets, we provide data aggregation services, analysis, biostatistics, and applications of machine learning algorithms to large repositories of images and other biomarker data seeking to advance the collective understanding and prediction capabilities for neurodegenerative diseases.

Spruce Biosciences, Inc.

Series B in 2020
Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. The company is driven by its mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal. They are committed to transforming the quality of life for patients who have been underserved by scientific innovation.

Eurobio-Scientific

Venture Round in 2004
Eurobio Scientific group is a French fully integrated leader in the field of in vitro diagnostics with expertise ranging from discovery to commercialization of specialty diagnostic solutions as well as products for research in life-science.

First Wave Bio, Inc.

Venture Round in 2018
First Wave Bio develops medical solutions to address the lack of effective and safe treatments for Inflammatory Bowel Disease (IBD). The solutions include a gut-restricted small molecule that can be formulated for either oral or rectal administration to treat ulcerative colitis among other IBDs, giving UC patients more accessible and cost-effective treatment.

Visterra

Series A in 2013
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Andrew Alliance S.A.

Series B in 2014
Andrew Alliance S.A. engages in the development and commercialization of robotics for the life sciences sector. The company offers OneLab, a graphical drag-and-drop design interface to perform a liquid handling operation; Andrew+, a pipetting robot that uses conventional electronic pipettes; Pipette, a device controlled by cloud software for ergonomics and minimizing execution errors and traceability; and Andrew, a portable liquid handling robot that operates totally unattended manual pipettes in laboratories. It also offers Andrew Assistant, a protocol design software program to design, verify, and document biology protocols that require quantitative liquid handling. The company sells its robot directly and through a network of distributor partners in Switzerland and internationally. Andrew Alliance S.A. was founded in 2011 and is based in Geneva, Switzerland with an additional office in Boston.

amunix

Series B in 2021
Amunix Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops protein and peptide therapeutics products for cancer. It focuses on XTEN, a half-life extension platform; XPAT (XTENylated Protease-Activated T Cell Engager) platform using its XTEN technology to analyze protease activity in the tumor microenvironment; and Protease Triggered Immune Activator (ProTIA), an immuno-oncology therapeutic. The company caters to the academic, biotechnology, and pharmaceutical sectors. It has strategic partnerships with Janssen, Biogen-Idec, Noxxon, Baxalta, Ambrx, Seattle Genetics, and Versartis. The company was formerly known as Amunix, Inc. Amunix Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Mountain View, California.

DBV Technologies S.A.

Venture Round in 2005
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of treatments in this field, they are investigating a potential new class of immunotherapy that aims to activate the immune system of patients through the skin.
Alpine Immune Sciences is an immunotherapy startup focused on developing recombinant, protein-based therapeutic solutions. It was founded on January 23, 2015, and is based in Seattle, Washington, United States.

Anjarium Biosciences AG

Series A in 2021
Anjarium Biosciences is a transforming exosomes from cellular message couriers to potent therapeutic carriers for debilitating diseases. By harnessing the delivery propensity of our body’s natural communication network, we are forward engineering evolution to build a product engine for a new generation of targeted nanomedicines. Anjarium’s Hybridosome® platform creates unmatched advantages in the realm of engineering exosomes to address the therapeutic areas of cancer and rare genetic diseases.

Median Technologies

Post in 2015
MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. The company standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. The company serves two primary markets: drug development and patient care. MEDIAN Technologies has a strategic partnership with a contract research organization to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market. MEDIAN Technologies was founded in 2002 and is based in Sophia-Antipolis, France.
Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

GelSight, Inc.

Series A in 2015
GelSight, Inc. provides extremely detailed and rapid surface measurements through the novel GelSight sensor technology. Our approach to metrology is flexible: the same core technology can be used to measure any rigid material at scales spanning four orders of magnitude. Still in its inception, GelSight, Inc. has already designed and manufactured prototypes for clients in aerospace, ballistics and metrology. As GelSight expands, we also look forward to learning more about your surface measurement needs.

Oxagen

Series C in 2009
Oxagen Limited, a biopharmaceutical company, develops and commercializes anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhinoconjunctivitis. Its drug programs target the CRTH2 receptor that initiates and maintains allergic conditions. The company develops a pipeline of small molecule drugs. It serves customers in the United Kingdom, Russia, CIS countries, and internationally. Oxagen Limited was incorporated in 1996 and is based in London, United Kingdom.

Artios Pharma

Series C in 2021
Artios Pharma Limited, a biotechnology company, focuses on developing cancer treatments that target DNA damage response (DDR) pathways to selectively kill cancer cells. Its product pipeline includes DNA polymerase theta (Polθ), which is involved in multiple processes associated with DNA repair; an in-licensed program that targets a protein that has been identified as a novel DNA damage response target; and a novel cancer treatment targeting DNA nucleases involved in the DDR. The company was incorporated in 2015 and is headquartered in Cambridge, United Kingdom.

Arrakis Therapeutics

Series B in 2019
Arrakis Therapeutics is a developer of a drug discovery platform intended to target RNA. The company's platform integrates leading-edge RNA bioinformatic and structural tools to produce a pipeline of rSMs to treat a range of disease including neurology, oncology and rare genetic diseases, enabling physicians to offer enhanced care.

Adagio Therapeutics, Inc.

Series C in 2021
Adagio Therapeutics, Inc., a biotechnology company, develops antibodies that neutralize SARS-CoV-2, SARS-CoV-1, and potentially emergent coronaviruses. Its portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

eTheRNA immunotherapies

Series B in 2022
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.
Paratek Pharmaceuticals, Inc. is a privately held biopharmaceutical company headquartered in Boston, MA, which is engaged in the discovery and commercialization of new therapeutics that treat life threatening infectious and other serious diseases.

Gossamer Bio, Inc.

Series A in 2018
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.

CinCor Pharma

Series B in 2021
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, develops clinical candidates for cardiovascular, metabolic, and kidney diseases. It focuses on developing CIN-107, a aldosterone synthase inhibitor for the treatment of resistant hypertension and primary aldosteronism. The company was founded in 2018 and is based in Cincinnati, Ohio.

Icosavax

Series B in 2021
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. tHEY were founded on breakthrough computationally-designed virus-like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington.

Alpine Immune Sciences

Funding Round in 2020
Alpine Immune Sciences is an immunotherapy startup focused on developing recombinant, protein-based therapeutic solutions. It was founded on January 23, 2015, and is based in Seattle, Washington, United States.

Santaris Pharma

Series C in 2007
Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.

ImpactRx

Series E in 2010
ImpactRx, Inc. operates as a promotion research organization for the pharmaceutical industry in the United States. The company tracks and evaluates the impact of pharmaceutical promotions on the prescribing behavior of the physicians. Its ImpactRx technology enables to collect and process the information on the perceptions and activities of physicians, as well as allows pharmaceutical companies to diagnose and predict the efficiency and effectiveness of sales and marketing initiatives. The company structures its data into a range of syndicated and semi-custom products in the areas of brand management and market research, sales management, managed care marketing, and oncology sales and marketing to assist pharmaceutical and biotech enterprises in decision making. ImpactRx, Inc. was founded in 2000 and is headquartered in Mount Laurel, New Jersey.

Telesta Therapeutics

Venture Round in 2015
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.

Endeavor BioMedicines

Series A in 2021
Endeavor BioMedicines is developing new treatments targeting the underlying causes of pulmonary fibrosis.

XTuit Pharmaceuticals

Series A in 2015
XTuit Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics targeting the disease-promoting microenvironment in fibrotic diseases and cancer. It develops pharmaceutical preparations for use in the diagnosis and treatment of oncological, tumor, and inflammatory diseases. The company was incorporated in 2011 and is based in Waltham, Massachusetts.
Scorpion Therapeutics, Inc., a biotechnology company, develops next-generation precision oncology technologies for the treatment of cancer. The company develops precision oncology drugs in three areas, including therapies against known oncogenes; agents for known but currently undruggable cancer targets; and drugs for new targets. Scorpion Therapeutics, Inc. was founded in 2020 and is based in Boston, Massachusetts.

Elixir Pharmaceuticals

Series D in 2009
Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.

Theseus Pharmaceuticals

Series B in 2021
Theseus Pharmaceuticals is a Technology based company.

JenaValve Technology

Series C in 2014
JenaValve's device idea was conceived by Hans-Reiner Figulla, MD, and Markus Ferrari, MD, both cardiologists at the Friedrich Schiller University Clinic, Jena, Germany. In 2006 the company was founded to develop second generation transcatheter aortic valve implantation (TAVI) systems for transapical and transfemoral implantation. At a very early state, it became clear to their research and development as well as clinical teams that safety, precision and durability are key for successful treatment, and ultimately, patient well-being.

Rectify Pharmaceuticals

Series A in 2021
Rectify is developing disease-modifying precision therapies that restore ABC transporter function to address the underlying cause of serious genetic diseases. The company’s pipeline spans multiple therapeutic areas.

Trevi Therapeutics, Inc.

Series C in 2018
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Its Haduvio (nalbuphine ER), which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease, as well as to treat chronic kidney disease-associated with pruritus. The company was founded in 2011 and is headquartered in New Haven, Connecticut.

Adagio Therapeutics, Inc.

Series B in 2020
Adagio Therapeutics, Inc., a biotechnology company, develops antibodies that neutralize SARS-CoV-2, SARS-CoV-1, and potentially emergent coronaviruses. Its portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Jounce Therapeutics, Inc.

Series B in 2015
Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine is driving this transformational approach, which has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures.

Atea Pharmaceuticals

Series D in 2020
Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses. Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.

Replimune Group

Series A in 2015
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Median Technologies

Post in 2014
MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. The company standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. The company serves two primary markets: drug development and patient care. MEDIAN Technologies has a strategic partnership with a contract research organization to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market. MEDIAN Technologies was founded in 2002 and is based in Sophia-Antipolis, France.

BioSilta Ltd.

Venture Round in 2014
BioSilta Ltd. develops reagent-based microbial growth systems. The company offers EnPresso B, a series of reagent-based solutions that focuses on recombinant protein yields from bacterial cultures and EnPresso Y Defined, a tablet-based chemically-defined growth system for yeast cultures. Additionally, it provides flasks, seals, and culture plates. BioSilta Ltd. was incorporated in 2014 and is headquartered in St. Ives, United Kingdom.

Anaconda BioMed

Series B in 2019
Anaconda Biomed, headquartered in Barcelona, Spain, is among the world's most innovative early stage medical technology companies. The company was founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, and is developing the ANCD BRAIN™, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS).
Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company’s orthobiologics pipeline products comprise MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products include KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion. The company has collaborations with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. Kuros Biosciences AG is based in Schlieren, Switzerland.

SpineVision

Venture Round in 2013
SpineVision is a spinal technology company focused on the development and marketing of implants and instrumentation for spinal treatment. The company offers spinal systems addressing a wide range of spinal pathologies including degenerative disc disease, deformity, cervical disorders, trauma and tumors. These products have been developed in collaboration with leading neurological and orthopedic surgeons which has resulted in over 20 patents. SpineVision was founded in 1999 and is headquartered in Antony in France, with subsidiaries in Belgium, Italy, the United Kingdom, and the United States.

Editas Medicine

Series B in 2015
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products. Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado.

Intarcia Therapeutics

Series B in 2007
Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.

Prevail Therapeutics

Series B in 2019
Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company’s lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson’s disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

Anaconda BioMed

Series A in 2017
Anaconda Biomed, headquartered in Barcelona, Spain, is among the world's most innovative early stage medical technology companies. The company was founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, and is developing the ANCD BRAIN™, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS).

Trevi Therapeutics, Inc.

Series C in 2017
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Its Haduvio (nalbuphine ER), which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease, as well as to treat chronic kidney disease-associated with pruritus. The company was founded in 2011 and is headquartered in New Haven, Connecticut.

Egalet

Series B in 2012
Egalet is a specialty pharmaceutical company that develops pain management products. The company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and has optimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids.

Replimune Group

Seed Round in 2015
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

JenaValve Technology

Series C in 2013
JenaValve's device idea was conceived by Hans-Reiner Figulla, MD, and Markus Ferrari, MD, both cardiologists at the Friedrich Schiller University Clinic, Jena, Germany. In 2006 the company was founded to develop second generation transcatheter aortic valve implantation (TAVI) systems for transapical and transfemoral implantation. At a very early state, it became clear to their research and development as well as clinical teams that safety, precision and durability are key for successful treatment, and ultimately, patient well-being.

Visterra

Series B in 2014
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Orqis Medical

Series D in 2007
ORQIS Medical Corporation operates as a medical device company. It develops and sells minimally invasive devices for improving cardiac performance through aortic flow therapy. It offers Cancion System, a heart failure treatment that uses continuous aortic flow augmentation technology to improve symptoms of heart failure and change the underlying course of the disease for patients hospitalized for de-compensated heart failure. The company’s products also include Exeleras System to treat chronic heart failure patients.
Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Nuvation Bio

Series A in 2019
Nuvation Bio Inc., a biopharmaceutical company, focuses on the development of therapies for oncology. Its portfolio includes various oncology programs with multiple drug development candidates. Nuvation Bio Inc.was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. The company was founded in 2018 and is based in New York, New York with an additional office in San Francisco, California.

ObsEva

Post in 2017
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2α, or PGF2α receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

ESSA Pharma

Post in 2018
ESSA is a pharmaceutical company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA is developing drugs that selectively block the N-terminal domain of the androgen receptor (AR). The AR is required for the growth and survival of most prostate cancer; therefore, the AR N-terminal domain is an ideal target for next-generation hormone therapy.

Kezar Life Sciences

Series B in 2017
Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergies between protein degradation and protein secretion, two fertile areas for drug discovery with platform potential.

Immunic AG

Series A in 2017
Immunic is a developer of oral drugs intended to help in the treatment of chronic inflammatory diseases. The company's drugs help to develop a small molecule immune modulators that block T helper type 1- and type 17-mediated immune and build autoimmune responses to treat conditions including inflammatory bowel disease (IBD) or psoriasis, enabling physicians to treat their patients in an enhanced way.

Kronos Bio, Inc.

Series A in 2019
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.

eTheRNA immunotherapies

Series A in 2016
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.

Kronos Bio, Inc.

Seed Round in 2018
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.

IFM Therapeutics, Inc.

Venture Round in 2019
IFM Therapeutics is a provider of small molecule that module novel targets in the innate immune system. The company and its academic collaborators combine unparalleled expertise in innate immunity with seasoned drug discovery and development professionals. Its subsidiary IFM Due is focused on the discovery and developing antagonists of the cGAS/STING pathway for the treatment of inflammation, neuroinflammation, autoimmunity and cancer. IFM Discovery, a newly financed incubator entity within the IFM enterprise, is prosecuting a basket of genetically-validated targets as next-generation therapies for inflammation, neuroinflammation, autoimmunity and fibrosis

Senti Biosciences, Inc.

Series A in 2018
Senti Biosciences is a team of bioengineers, scientists, and entrepreneurs on a mission to treat the most complex and challenging diseases. Led by pioneers in synthetic biology and computation, Senti is using the latest techniques in the fields to build the future of gene and cell-based therapies. Senti’s proprietary synthetic biology platform provides fundamental advantages for therapeutics development. Senti Biosciences is a resident company of Johnson & Johnson Innovation, JLABS at South San Francisco (JLABS @ SSF).

Kyn Therapeutics

Series B in 2021
Ikena Oncology is dedicated to bringing next generation oncology therapies to patients suffering from cancer. Ikena Oncology are committed to leveraging our unique understanding of the complex biologic pathways that drive the formation and spread of cancers to discover and develop novel, patient-directed therapies. Selecting patients for treatment in clinical studies with biomarkers we develop is at the core of our strategy.

LEXEO Therapeutics

Series A in 2021
LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (single genemutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline.

Visterra

Series C in 2017
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Eve.com

Venture Round in 1999
EVE offers massively multiplayer online roleplaying games. The company’s portfolio includes Eve Online, Eve Valkyrie, Gunjack, Dust 514, and Eve Universe.

Dicerna Pharmaceuticals

Series C in 2013
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others. The company was founded in 2007 and is headquartered in Lexington, Massachusetts.

Nuvation Bio

Post in 2020
Nuvation Bio Inc., a biopharmaceutical company, focuses on the development of therapies for oncology. Its portfolio includes various oncology programs with multiple drug development candidates. Nuvation Bio Inc.was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. The company was founded in 2018 and is based in New York, New York with an additional office in San Francisco, California.

Celletra

Venture Round in 2005
Celletra, Ltd. engages in the development and manufacture of wireless network enhancement solutions. Its products and services include CellEnhancer that provide power and sensitivity enhancement of the existing base stations; CellShaper load balancing system; CellExtender for base station extensions and repeaters; and CellRepeater, which provides coverage of three separate sectors that are served by the same donor front-end. The company also provides Two-Lobe Repeaters, a single-unit repeater that emits two separate lobes; RF and Fiber Repeaters, which provides medium to high power RF and fiber repeaters; and Modular Repeaters for distributed installation, as well as technical support services. Its solutions enable network operators to deliver expanded network coverage on their existing networks. The company was incorporated in 1997 and is based in Yokne'am Ilit, Israel. It has a subsidiary in New Jersey. As of August 17, 2006, Celletra, Ltd. operates as a subsidiary of Unity Wireless Corp.
Sienna Biopharmaceuticals (“sienna”) is a company focused on the discovery, clinical development and commercialization of products in aesthetics and dermatology based on scientific breakthroughs that dramatically improve patient outcomes and physicians’ practice of medicine.

Morphic Holding, Inc.

Series B in 2018
Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Drawing on discoveries made in the lab of Scientific Founder Tim Springer, Morphic was created in 2015 with co-founders Polaris Partners, T.A. Springer and Schrödinger, Inc., along with ShangPharma Investment Group.

FoRx Therapeutics

Seed Round in 2020
FoRx Therapeutics AG, a biotechnology company, develops therapeutics for the treatment of cancer. The company engages in drugging key molecular targets involved in DNA replication stress towards the development of targeted anticancer drugs. The company was founded in 2019 and is based in Basel, Switzerland.

Gossamer Bio, Inc.

Series B in 2018
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.

Arcutis Biotherapeutics

Series C in 2019
Arcutis Biotherapeutics is a privately held clinical-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology.

Prevail Therapeutics

Series A in 2018
Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company’s lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson’s disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

Translate Bio

Series A in 2012
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.

Kronos Bio, Inc.

Private Equity Round in 2020
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.
Scorpion Therapeutics, Inc., a biotechnology company, develops next-generation precision oncology technologies for the treatment of cancer. The company develops precision oncology drugs in three areas, including therapies against known oncogenes; agents for known but currently undruggable cancer targets; and drugs for new targets. Scorpion Therapeutics, Inc. was founded in 2020 and is based in Boston, Massachusetts.

Trevi Therapeutics, Inc.

Series C in 2019
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Its Haduvio (nalbuphine ER), which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease, as well as to treat chronic kidney disease-associated with pruritus. The company was founded in 2011 and is headquartered in New Haven, Connecticut.

Chord Therapeutics SA

Series A in 2020
Chord Therapeutics is a clinical-stage pharmaceutical company developing drugs for patients with rare, life-threatening, and severely disabling diseases. The company is advancing its lead drug candidate CRD1 under orphan drug designation for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and myasthenia gravis (MG). The company was founded in 2014 and based in Geneva, Switzerland.

Attenua

Series A in 2018
Attenua, Inc. is a virtual biotech company formed to develop therapies for debilitating conditions neglected by Big Pharma's shift to specialty Pharma and biologics. They believe small molecule Blockbuster drugs that would benefit millions are still to be discovered. They have assembled a team of leading scientists and ex-Big Pharma advisors with many years of drug development expertise. Their team has previous work experience at Merck, GSK, AstraZeneca, and Genentech.

Translate Bio

Series C in 2017
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.

Translate Bio

Series C in 2017
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.

Egalet

Post in 2014
Egalet is a specialty pharmaceutical company that develops pain management products. The company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and has optimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids.

Replimune Group

Series B in 2017
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Translate Bio

Series B in 2015
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.

eTheRNA immunotherapies

Series B in 2020
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.

Andrew Alliance S.A.

Series C in 2018
Andrew Alliance S.A. engages in the development and commercialization of robotics for the life sciences sector. The company offers OneLab, a graphical drag-and-drop design interface to perform a liquid handling operation; Andrew+, a pipetting robot that uses conventional electronic pipettes; Pipette, a device controlled by cloud software for ergonomics and minimizing execution errors and traceability; and Andrew, a portable liquid handling robot that operates totally unattended manual pipettes in laboratories. It also offers Andrew Assistant, a protocol design software program to design, verify, and document biology protocols that require quantitative liquid handling. The company sells its robot directly and through a network of distributor partners in Switzerland and internationally. Andrew Alliance S.A. was founded in 2011 and is based in Geneva, Switzerland with an additional office in Boston.

Beam Therapeutics Inc.

Series B in 2019
Over half of the genetic errors associated with disease result from a single-letter change in the billions of bases that form the genome. In other cases, certain natural genetic variations in DNA are known to protect against disease. By changing a single letter – to eliminate errors or write in protective changes – in enough cells, base editing may help us prevent, modify, and even cure a wide range of diseases affecting patients’ lives.

Kezar Life Sciences

Series A in 2015
Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergies between protein degradation and protein secretion, two fertile areas for drug discovery with platform potential.

Imago BioSciences, Inc.

Series B in 2019
Imago BioSciences, Inc., a biotechnology company, engages in developing medicines based on the science of genetics and epigenetics for the treatment of hematologic diseases. The company focuses on therapeutics that alter gene expression patterns. It develops medicines for hematologic diseases that result in bone marrow failure or leukemia, myelodysplastic syndrome, acute myelogenous leukemia, and other diseases. The company was incorporated in 2012 and is based in San Carlos, California.

Sana Biotechnology, Inc.

Series A in 2020
Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases. The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.

Imago BioSciences, Inc.

Series C in 2020
Imago BioSciences, Inc., a biotechnology company, engages in developing medicines based on the science of genetics and epigenetics for the treatment of hematologic diseases. The company focuses on therapeutics that alter gene expression patterns. It develops medicines for hematologic diseases that result in bone marrow failure or leukemia, myelodysplastic syndrome, acute myelogenous leukemia, and other diseases. The company was incorporated in 2012 and is based in San Carlos, California.